Table of Contents
ISRN Oncology
Volume 2011, Article ID 708343, 5 pages
http://dx.doi.org/10.5402/2011/708343
Clinical Study

Does Radioiodine Therapy in Patients with Differentiated Thyroid Cancer Increase the Frequency of Another Malignant Neoplasm?

1Departamento de Clinica Medica, Faculdade de Medicina (FMB), UNESP, Rubiao Junior s/n, Botucatu, 18618-000 São Paulo, Brazil
2Departamento de Oftalmologia e Otorrinolaringologia, Faculdade de Medicina (FMB), UNESP, Rubiao Junior s/n, Botucatu, 18618-000 São Paulo, Brazil
3Departamento de Patologia, Faculdade de Medicina (FMB), UNESP, Rubiao Junior s/n, Botucatu, 18618-000 São Paulo, Brazil
4Servico de Medicina Nuclear, Faculdade de Medicina (FMB), UNESP, Rubiao Junior s/n, Botucatu, 18618-000 São Paulo, Brazil
5Servico de Medicina Nuclear, Santa Casa de Sao Paulo, Rua Cesario Mota Junior, 112 ,Vila Buarque, 01221-020 São Paulo, Brazil
6Departamento de Bioestatistica, Instituto de Biociencias, UNESP, Rubiao Junior s/n, Botucatu, 18618-000 São Paulo, Brazil

Received 7 June 2011; Accepted 30 June 2011

Academic Editor: J. E. Tyczynski

Copyright © 2011 Renata Midori Hirosawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives. To compare the frequency of another primary malignancy in patients with differentiated thyroid carcinoma (DTC) who received radioiodine therapy or not (131I). Material and Methods. 168 cases of DTC patients were retrospectively evaluated as to the frequency of another neoplasia by comparing patients with and without it, taking into account clinical, laboratory, and therapeutic parameters. Results. Another primary malignancy occurred in 8.9% of patients. Of these, 53.3% showed the malignancy before 131I and 46.7% after it. By comparing both groups, the age at the moment of diagnosis of another neoplasia was 46.1 ± 20.2 years for the group before 131I therapy and of 69.4 ± 11.4 years for the group after it ( 𝑃 = 0 . 0 2 ). Of the 148 patients treated with 131I, 4.7% developed another malignancy. The latter were older (61 ± 17 years) than those who did not show another cancer type (44.1 ± 14.2 years) ( 𝑃 < 0 . 0 5 ). Conclusion. The frequency of another neoplasia found after 131I was similar to that found before 131I.